Identification of hypoxic gene-signature as a prognostic and predictive biomarker to determine effective therapy in high risk bladder cancer patients. - PubMed - NCBI

Identification of hypoxic gene-signature as a prognostic and predictive biomarker to determine effective therapy in high risk bladder cancer patients. - PubMed - NCBI

Transl Androl Urol. 2018 Mar;7(Suppl 1):S104-S106. doi: 10.21037/tau.2017.12.17.

Identification of hypoxic gene-signature as a prognostic and predictive biomarker to determine effective therapy in high risk bladder cancer patients.

Tan Z1, D'Costa NM1, Raven PA1, Chavez-Munoz C1, So AI1.

Author information

Comment on

• A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients. [Clin Cancer Res. 2017]

PMID:

 

29644173

 

PMCID:

 

PMC5881214

 

DOI:

 

10.21037/tau.2017.12.17

Free PMC Article